Company intelligence / Profile preview

FF Gene Biotech

Fuzhou, Fujian, China

Ownership: Private
Development stage: Other

Overview

FF Gene Biotech has established a commercial footprint in China focused primarily on NGS-based clinical diagnostics for cancer, reproductive health, and pediatric applications, serving over 50,000 test volumes and generating revenues above $10 million since launch.

Therapeutic areas: Women's HealthOncologyOther
Modalities: Next Generation SequencingDiagnostic testing (clinical genomics)Genetic testing
Industry: Molecular Diagnostics

Partnerships

Fulgent Genetics (parental strategic control)Xilong ScientificFuzhou Jinqiang Investment Partnership

Beyond the preview

Go deeper on FF Gene Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FF Gene Biotech.

Explore the full profile